Photothermal/nitric oxide synergistic anti-tumour therapy based on MOF-derived carbon composite nanoparticles

Nanoscale. 2022 Nov 10;14(43):16193-16207. doi: 10.1039/d2nr03027f.

Abstract

Conventional organic photothermal conversion reagents still face some challenges for their real applications, such as the requirement of carriers for in vivo transport, uncontrolled degradation during use, reduction in photothermal conversion efficiency by repeated exposure to a near-infrared laser, and so on. Herein, uniform ZIF-8 nanoparticles were prepared first, and then carbonized and etched to form porous carbon nanoparticles (CNPs). After loading an NO donor and wrapping with red blood cell membrane, the novel CNP-NO@RBC photothermal agent integrated with in situ imaging ability was obtained. Due to the great photothermal conversion efficiency of the carbon material and the specific release of NO from the loaded NO conformer, the CNP-NO@RBCs show excellent tumour cell killing ability based on light-triggered photothermal/gas therapy at lower doses of CNP-NO@RBCs.

MeSH terms

  • Carbon / pharmacology
  • Cell Line, Tumor
  • Doxorubicin
  • Humans
  • Hyperthermia, Induced* / methods
  • Nanoparticles* / therapeutic use
  • Neoplasms* / pathology
  • Neoplasms* / therapy
  • Nitric Oxide
  • Phototherapy / methods

Substances

  • Nitric Oxide
  • Doxorubicin
  • Carbon